Camurus AB (publ)

    Jurisdiction
    Sweden
    LEI
    5493003S6Z6VI7WYFQ06
    ISIN
    SE0007692850 (CAMX.ST)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    54 / 100
    Better than peer group:
    51 / 100
    Fair value (Benjamin Graham formula)
    €68.76 15.0% undervalued
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €202.98M
    Gross margin
    93.5%
    EBIT
    €75.12M
    EBIT margin
    37.0%
    Net income
    €64.33M
    Net margin
    31.7%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €337.37M +66.2% €137.17M +113.2%
    €451.97M +34.0% €186.98M +36.3%
    €605.67M +34.0% €255.79M +36.8%

    Dividends

    No dividend payouts

    Add to watchlist

    Notifications